Global metabolomics identifies new extracellular biomarkers of nanovibration-driven mesenchymal stem cells osteodifferentiation.
Bispo DSC., Graça I., Haggarty JH., Reis A., McCormick MP., Bartlome S.
Laboratory Study, published in Biomater Adv (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Biomater Adv (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41129959
- DOI
- 10.1016/j.bioadv.2025.214567
Abstract (original English)
Bone-related conditions are a leading cause of disability and rising healthcare costs, prompting interest in tissue engineering solutions using mesenchymal stem cells (MSC). As part of an effort to eliminate synthetic osteogenic compounds, this study characterizes the metabolic adaptations of MSC to chemical-free nanovibration (or nanokicking, NK)-induced osteodifferentiation. Through articulation of conventional gene/protein/functional markers and a global metabolomics/lipidomics strategy, our findings indicate successful slow-paced osteodifferentiation, expressed by subtle and partially reversible intracellular changes, and pronounced, largely irreversible, extracellular alterations. The initial 7 days post-stimulation are accompanied by high energy demands and phosphocholine hydrolysis, both effects attenuated thereafter. In contrast, early membrane remodeling persists until day 21, possibly to facilitate increased membrane fluidity, vesicle formation and activated signaling cascades. Also after day 7, increased antioxidant activity, redox regulation, and glycerolipid redirection towards phospholipid biosynthesis are evident. Concurrent sphingolipid modulation may support the synthesis of bioactive lipids, phosphate production for mineralization and lipid raft assembly. NK was reinforced as a more targeted osteocommitment induction strategy, compared to traditional protocols
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.